Enovis Corp (ENOV) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Enovis Corp (ENOV) stock forecast summary
On Oct. 16, 2026, ENOV is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
Enovis Corp is a small-cap company with a market capitalization of $1.13B. It ranks number 8 by market capitalization among the 27 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.
For ENOV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 11.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ENOV included.
Follow ENOV freeENOV price chart and AI forecast
How ENOV ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Enovis Corp (ENOV) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
Valuation & Market
| Metric | ENOV | Rank |
|---|---|---|
| Market Cap | $1.13B | 8/27 |
| P/B Ratio | 0.76x | 18/22 |
| EPS | $-20.13 | – |
| Book Value/Share | $25.61 | – |
| Revenue/Share | $39.82 | – |
| FCF/Share | $1.10 | – |
Profitability & Margins
| Metric | ENOV | Rank |
|---|---|---|
| ROE | -74.6% | 12/19 |
| ROA | -29.2% | 12/19 |
| ROIC | -32.9% | 14/22 |
| Gross Margin | 61.1% | 9/20 |
| Operating Margin | -45.1% | 13/21 |
| Net Margin | -48.0% | 14/17 |
| EBT Margin | -46.5% | 13/21 |
| Tax Rate | -2.9% | – |
Financial Health
| Metric | ENOV | Rank |
|---|---|---|
| Current Ratio | 1.98x | 18/25 |
| Quick Ratio | 1.00x | 20/22 |
| D/E Ratio | 1.55x | 6/24 |
| Financial Leverage | 2.55x | 6/24 |
| Interest Coverage | 2.2x | 6/21 |
| Working Capital | $603M | 7/25 |
Cash Flow
| Metric | ENOV | Rank |
|---|---|---|
| Operating Cash Flow | $270M | 7/25 |
| Free Cash Flow | $64M | 6/16 |
| Capital Spending | -$206M | 14/16 |
| OCF Growth YoY | 43.6% | 3/10 |
| FCF/Sales | 2.8% | 8/16 |
| CapEx/Sales | 9.0% | 2/16 |
Operational Efficiency
| Metric | ENOV | Rank |
|---|---|---|
| Asset Turnover | 0.61x | 13/18 |
| Receivables Turnover | 5.2x | 11/17 |
| Inventory Turnover | 1.5x | 16/22 |
| Fixed Assets Turnover | 4.3x | 11/19 |
| Days Sales Outstanding | 70 days | 7/17 |
| Days Inventory | 246 days | 7/22 |
| Payables Period | 79 days | 7/19 |
| Cash Conversion Cycle | 237 days | 3/15 |
Income Statement
| Metric | ENOV | Rank |
|---|---|---|
| Total Revenue | $2.30B | 4/19 |
| Operating Income | -$1.04B | 25/25 |
| Net Income | -$1.10B | 19/19 |
| R&D Expense | $124M | 5/22 |
| SG&A Expense | $1.08B | 6/22 |
| Cost of Goods Sold | $894M | 7/22 |
Dividend & Shareholder Information
| Metric | ENOV | Rank |
|---|---|---|
| Shares Outstanding | 58M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.21B | 32.3% of assets |
| Cash & Short-term Investments | $13M | 0.3% of assets |
| Accounts Receivable | $442M | 11.7% of assets |
| Inventory | $602M | 16.0% of assets |
| Total Liabilities | $2.29B | 60.7% of assets |
| Short-term Debt | $418M | 11.1% of assets |
ENOV quarterly financials and insider trading
Enovis Corp (ENOV) industry peers
Companies classified under the same SEC industry code as Enovis Corp (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| ENOV Enovis Corp | ▶ | $1.13B |
| ISRG Intuitive Surgical Inc | ▼ | $150.74B |
| STE Steris Plc | ▼ | $21.71B |
| ZBH Zimmer Biomet Holdings, Inc. | ▼ | $18.12B |
| SNN Smith & Nephew Plc | ▼ | $12.75B |
| ALGN Align Technology Inc | ▶ | $10.46B |
| MSA Msa Safety Inc | ▼ | $6.91B |
| ESTA Establishment Labs Holdings Inc. | ▲ | $1.76B |
| CDRE Cadre Holdings, Inc. | ▶ | $1.13B |
| AVR Anteris Technologies Global Corp. | ▶ | $590M |
| SMTI Sanara Medtech Inc. | ▼ | $305M |
| INGN Inogen Inc | ▶ | $166M |
| LAKE Lakeland Industries Inc | ▲ | $90M |
| NTRB Nutriband Inc. | ▲ | $76M |
| APT Alpha Pro Tech Ltd | ▶ | $57M |
| COCH Envoy Medical, Inc. | ▶ | $52M |
| MYO Myomo, Inc. | ▲ | $48M |
| MLSS Milestone Scientific Inc. | ▲ | $29M |
| LFWD Lifeward Ltd. | ▲ | $17M |
| CUPR Cuprina Holdings (Cayman) Ltd | ▶ | $13M |
| UEEC United Health Products, Inc. | ▲ | $12M |
| RGNT Regentis Biomaterials Ltd. | ▲ | $10M |
| CLGN Collplant Biotechnologies Ltd | ▶ | $7M |
| LGMK Logicmark, Inc. | ▲ | $1M |
| BBLG Bone Biologics Corp | ▲ | $1M |
| RBOT Vicarious Surgical Inc. | ▲ | $550K |
| FEED Envue Medical, Inc. | ▼ | $340K |
Where ENOV sits on the market map
Enovis Corp (ENOV) stock news
Loading...
Enovis Corp (ENOV) stock forecast FAQ
What is the Enovis Corp (ENOV) stock forecast?
On Oct. 16, 2026, ENOV is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Enovis Corp stock predictions?
For ENOV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 11.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Enovis Corp forecasts updated?
Enovis Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Enovis Corp's industry peers?
27 issuers in our coverage, ENOV included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Smith & Nephew Plc (SNN), Align Technology Inc (ALGN), Msa Safety Inc (MSA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.